The forthcoming programme at EANS2018 demonstrates that Zeiss are active and will have Kinevo and Convivo on show together. Scientific papers show where Convivo is available for use to a growing scientific audience. Medical companies are adept at marketing "subject to FDA approval". I am less concerned about the actions of Zeiss than I am about the actions of a BOD which hasn't even mentioned EANS2018 in Brussels and where the last news item on the wesite is October, 2017.
Competent hard working management, page-49
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.010(6.45%) |
Mkt cap ! $129.4M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 16.0¢ | $23.08K | 143.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49548 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 73836 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| OIL (ASX) Chart |
